These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 26167247)

  • 1. Nucleos(t)ide analogs in the prevention of hepatitis B virus related hepatocellular carcinoma.
    Baran B
    World J Hepatol; 2015 Jul; 7(13):1742-54. PubMed ID: 26167247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk for hepatocellular carcinoma in the course of chronic hepatitis B virus infection and the protective effect of therapy with nucleos(t)ide analogues.
    Rapti I; Hadziyannis S
    World J Hepatol; 2015 May; 7(8):1064-73. PubMed ID: 26052395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Oral nucleos(t)ide analogues antiviral therapy reduces HBV-related HCC: consensus and contention].
    Han C; Dou XG
    Zhonghua Gan Zang Bing Za Zhi; 2021 Apr; 29(4):293-296. PubMed ID: 33979951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatocellular Carcinoma and Hepatitis: Advanced Diagnosis and Management with a Focus on the Prevention of Hepatitis B-Related Hepatocellular Carcinoma.
    Kim SR; Kim SK
    Diagnostics (Basel); 2023 Oct; 13(20):. PubMed ID: 37892033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiviral treatment to prevent chronic hepatitis B or C-related hepatocellular carcinoma.
    Chen LP; Zhao J; Du Y; Han YF; Su T; Zhang HW; Cao GW
    World J Virol; 2012 Dec; 1(6):174-83. PubMed ID: 24175223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update Treatment for HBV Infection and Persistent Risk for Hepatocellular Carcinoma: Prospect for an HBV Cure.
    Yoo J; Hann HW; Coben R; Conn M; DiMarino AJ
    Diseases; 2018 Apr; 6(2):. PubMed ID: 29677098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices: A 12-year prospective cohort study.
    Lampertico P; Invernizzi F; Viganò M; Loglio A; Mangia G; Facchetti F; Primignani M; Jovani M; Iavarone M; Fraquelli M; Casazza G; de Franchis R; Colombo M
    J Hepatol; 2015 Nov; 63(5):1118-25. PubMed ID: 26100495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Timing and selection of antiviral therapy with nucleos(t)ide analogues for prevention of hepatitis B virus-related HCC].
    Han C; Lai PP; Dou XG
    Zhonghua Gan Zang Bing Za Zhi; 2019 Nov; 27(11):827-830. PubMed ID: 31941235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review.
    Papatheodoridis GV; Lampertico P; Manolakopoulos S; Lok A
    J Hepatol; 2010 Aug; 53(2):348-56. PubMed ID: 20483498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of HBV and HBV/HDV-Associated Liver Cirrhosis.
    Höner Zu Siederdissen C; Cornberg M
    Visc Med; 2016 Apr; 32(2):86-94. PubMed ID: 27413725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of antiviral therapy in patients with chronic hepatitis B and cirrhosis.
    Okada M; Enomoto M; Kawada N; Nguyen MH
    Expert Rev Gastroenterol Hepatol; 2017 Dec; 11(12):1095-1104. PubMed ID: 28752768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peginterferon Is Superior to Nucleos(t)ide Analogues for Prevention of Hepatocellular Carcinoma in Chronic Hepatitis B.
    Liang KH; Hsu CW; Chang ML; Chen YC; Lai MW; Yeh CT
    J Infect Dis; 2016 Mar; 213(6):966-74. PubMed ID: 26582959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy.
    Papatheodoridis GV; Chan HL; Hansen BE; Janssen HL; Lampertico P
    J Hepatol; 2015 Apr; 62(4):956-67. PubMed ID: 25595883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study.
    Papatheodoridis GV; Manolakopoulos S; Touloumi G; Vourli G; Raptopoulou-Gigi M; Vafiadis-Zoumbouli I; Vasiliadis T; Mimidis K; Gogos C; Ketikoglou I; Manesis EK;
    Gut; 2011 Aug; 60(8):1109-16. PubMed ID: 21270118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Viral hepatitis B and hepatocellular carcinoma.
    Michielsen P; Ho E
    Acta Gastroenterol Belg; 2011 Mar; 74(1):4-8. PubMed ID: 21563647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency.
    Wong DK; Seto WK; Fung J; Ip P; Huang FY; Lai CL; Yuen MF
    Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1004-10.e1. PubMed ID: 23376799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of chronic hepatitis B virus infection - Dutch national guidelines.
    Buster EH; van Erpecum KJ; Schalm SW; Zaaijer HL; Brouwer JT; Gelderblom HC; de Knegt RJ; Minke Bakker C; Reesink HW; Janssen HL;
    Neth J Med; 2008; 66(7):292-306. PubMed ID: 18663260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of hepatitis B virus genotypes B and C among chronically hepatitis B virus-infected patients who received nucleos(t)ide analogs: A multicenter retrospective study.
    Inoue J; Akahane T; Nakayama H; Kimura O; Kobayashi T; Kisara N; Sato T; Morosawa T; Izuma M; Kakazu E; Ninomiya M; Iwata T; Takai S; Nakamura T; Sano A; Niitsuma H; Masamune A;
    Hepatol Res; 2019 Nov; 49(11):1263-1274. PubMed ID: 31254482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention and risk factors of hepatitis B recurrence after living donor liver transplantation.
    Na GH; Kim DG; Han JH; Kim EY; Lee SH; Hong TH; You YK; Choi JY
    J Gastroenterol Hepatol; 2014 Jan; 29(1):151-6. PubMed ID: 24117684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis B Virus Treatment and Hepatocellular Carcinoma: Controversies and Approaches to Consensus.
    Kim SK; Fujii T; Kim SR; Nakai A; Lim YS; Hagiwara S; Kudo M
    Liver Cancer; 2022 Dec; 11(6):497-510. PubMed ID: 36589728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.